Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$5.79 +2.3%	$6.64	$5.20 ▼ $15.60	$10.85M	0.91	10,871 shs	10,070 shs
CRIS Curis	$2.16 -6.1%	$2.03	$1.02 ▼ $8.42	$24.06M	3.69	73,883 shs	65,603 shs
SABS SAB Biotherapeutics	$1.79 +0.6%	$1.72	$1.00 ▼ $5.01	$16.53M	0.55	66,813 shs	11,931 shs
SGYP Synergy Pharmaceuticals		$0.02	$0.03 ▼ $2.23	$7.44M	4.94	6.08 million shs	N/A

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	0.00%	-9.15%	-14.16%	-35.54%	-61.50%
CRIS Curis	0.00%	-16.97%	+8.49%	-13.53%	-70.51%
SABS SAB Biotherapeutics	0.00%	-2.79%	-3.40%	+3.49%	-31.01%
SGYP Synergy Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BOLT Bolt Biotherapeutics	2.7971 of 5 stars	3.2	5.0	0.0	0.0	0.6	1.7	1.3
CRIS Curis	2.4023 of 5 stars	3.5	3.0	0.0	0.0	3.1	0.0	0.6
SABS SAB Biotherapeutics	3.447 of 5 stars	3.5	5.0	0.0	0.0	0.0	1.7	1.3
SGYP Synergy Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.33	Hold	$50.00	763.56% Upside
CRIS Curis	3.00	Buy	$17.00	687.04% Upside
SABS SAB Biotherapeutics	3.00	Buy	$13.25	640.22% Upside
SGYP Synergy Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SGYP, BOLT, SABS, and CRIS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	BOLT Bolt Biotherapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/19/2025	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00
5/15/2025	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/14/2025	SABS SAB Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/13/2025	BOLT Bolt Biotherapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$25.00 ➝ $20.00
4/1/2025	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
4/1/2025	SABS SAB Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/31/2025	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $16.00
3/25/2025	BOLT Bolt Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/25/2025	BOLT Bolt Biotherapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$30.00 ➝ $25.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$7.69M	1.45	N/A	N/A	$29.89 per share	0.19
CRIS Curis	$11.20M	2.02	N/A	N/A	($0.71) per share	-3.04
SABS SAB Biotherapeutics	$1.32M	12.60	N/A	N/A	$2.81 per share	0.64
SGYP Synergy Pharmaceuticals	$16.82M	0.00	N/A	N/A	($0.02) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$63.12M	-$33.40	N/A	N/A	N/A	-665.56%	-94.51%	-59.07%	8/12/2025 (Estimated)
CRIS Curis	-$43.39M	-$6.23	N/A	N/A	N/A	-376.08%	-923.37%	-97.14%	7/30/2025 (Estimated)
SABS SAB Biotherapeutics	-$34.10M	-$3.70	N/A	N/A	N/A	N/A	-105.14%	-69.24%	8/6/2025 (Estimated)
SGYP Synergy Pharmaceuticals	-$224.33M	-$1.02	N/A	N/A	N/A	-332.11%	N/A	-118.14%	N/A

Latest SGYP, BOLT, SABS, and CRIS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BOLT Bolt Biotherapeutics	-$6.80	-$5.80	+$1.00	-$0.29	$0.77 million	$1.22 million
5/9/2025	Q1 2025	SABS SAB Biotherapeutics	-$1.00	-$0.56	+$0.44	-$0.56	$0.13 million	N/A
5/6/2025	Q1 2025	CRIS Curis	-$1.14	-$1.25	-$0.11	-$1.25	$2.37 million	$2.38 million
3/31/2025	Q4 2024	CRIS Curis	-$1.36	-$1.25	+$0.11	-$1.25	$2.04 million	$2.70 million
3/28/2025	Q4 2024	SABS SAB Biotherapeutics	-$1.16	-$1.23	-$0.07	-$1.23	$0.12 million	$0.05 million
3/24/2025	Q4 2024	BOLT Bolt Biotherapeutics	-$7.60	-$7.60	N/A	-$0.42	$0.79 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CRIS Curis	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SGYP Synergy Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	0.48	3.13	3.13
CRIS Curis	N/A	1.23	1.23
SABS SAB Biotherapeutics	0.15	1.69	1.69
SGYP Synergy Pharmaceuticals	N/A	0.52	0.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
CRIS Curis	29.97%
SABS SAB Biotherapeutics	7.82%
SGYP Synergy Pharmaceuticals	28.47%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	6.10%
CRIS Curis	5.45%
SABS SAB Biotherapeutics	27.77%
SGYP Synergy Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	90	1.92 million	1.80 million	Not Optionable
CRIS Curis	60	10.46 million	9.89 million	No Data
SABS SAB Biotherapeutics	140	9.29 million	6.71 million	Not Optionable
SGYP Synergy Pharmaceuticals	N/A	248.04 million	N/A	Optionable

SGYP, BOLT, SABS, and CRIS Headlines

Recent News About These Companies

Strong Buy Rating for Syndax Pharmaceuticals Driven by Promising Pipeline and Solid Financials

November 6, 2024 | markets.businessinsider.com

Gen Z: The untapped audience

October 19, 2024 | pharmaphorum.com

Synergy Pharmaceuticals

August 9, 2024 | thepharmaletter.com

Jose Solorio

April 12, 2024 | seekingalpha.com

Synergy starts construction on one of Australia’s biggest batteries

March 19, 2024 | power-technology.com

PYC Therapeutics and Google Cloud partner for new precision medicines

January 2, 2024 | msn.com

Synergy Pharma Investors Win Revival of Suit Over Stock Dilution

August 28, 2023 | news.bloomberglaw.com

Avia Solutions Group acquires UK airline Synergy Aviation

July 17, 2023 | stattimes.com

Dental Association Calls for Synergy Between Public, Private Practices

June 15, 2023 | thisdaylive.com

Synergy Pharmaceuticals Inc Unit (SGYPU)

May 9, 2023 | investing.com

Market Factor Synergy Signals Exciting Growth For Digital Pathology

April 12, 2023 | forbes.com

HPCL signs pact with BPCL for hydrogen synergy

April 4, 2023 | auto.economictimes.indiatimes.com

Different resistors

March 29, 2023 | bbc.co.uk

Mains cables

March 28, 2023 | bbc.co.uk

Energy changes in braking

March 28, 2023 | bbc.co.uk

Blues plans launch Synergie to cut costs for the priciest drugs

January 8, 2023 | modernhealthcare.com

Synergy Pharmaceuticals (SGYP) Stock Higher in After-Hours Trading Following Paulson Investment

December 18, 2022 | thestreet.com

Jiangxi Synergy Pharmaceutical Co Ltd (300636)

September 13, 2022 | investing.com

i-Synergy’s Ledger Labs provides software development in blockchain and AI to business

July 25, 2022 | stockhead.com.au

Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call Transcript

May 16, 2022 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGYP, BOLT, SABS, and CRIS Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$5.79 +0.13 (+2.30%)

Closing price 04:00 PM Eastern

Extended Trading

$5.84 +0.05 (+0.93%)

As of 05:57 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Curis NASDAQ:CRIS

$2.16 -0.14 (-6.09%)

Closing price 04:00 PM Eastern

Extended Trading

$2.14 -0.02 (-0.69%)

As of 07:58 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

SAB Biotherapeutics NASDAQ:SABS

$1.79 +0.01 (+0.56%)

Closing price 04:00 PM Eastern

Extended Trading

$1.78 -0.01 (-0.34%)

As of 05:02 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

Synergy Pharmaceuticals NASDAQ:SGYP

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time